Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol Oral Solution in pediatric ASD
NCT04745026Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of cannabidiol in Autism Spectrum Disorder (ASD), sponsored by Jazz Pharmaceuticals plc. Started May 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04745026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745026.